Beta Bionics, Inc. SEC Filings

Beta Bionics, Inc. has updated expectations for Mint, its patch insulin pump in development. The company now expects to fully commercialize Mint by the end of the second quarter of 2027, subject to U.S. FDA regulatory clearance of its alternate controller enabled (ACE) insulin pump 510(k) application.

The new timeline reflects the FDA’s initial responses to that application and progress in scaling Mint manufacturing, and the company expects capacity to meet anticipated demand at launch. Mint is expected to offer a 200‑unit insulin reservoir, about three days of wear plus a 12‑hour grace period, smartphone control, waterproof use, and compatibility with leading continuous glucose monitors and Beta Bionics’ FDA‑approved fully adaptive dosing algorithm.

Beta Bionics, Inc. Schedule 13G/A: Eventide Asset Management, LLC and associated filers report beneficial ownership of 5,945,488 shares of Common Stock, representing 13.4% of the outstanding shares as of 03/31/2026. The filing states the shares are held by Eventide funds and separately managed accounts and that the filers disclaim beneficial ownership in accordance with Rule 13d-4.

RTW Investments and Roderick Wong report a 2,000,000-share position in Beta Bionics, Inc. The filing amends prior disclosures and shows the Reporting Persons share voting and dispositive power over 2,000,000 shares, representing 4.5% of the common stock based on 44,561,695 shares outstanding as of March 23, 2026. The shares are held on behalf of the RTW Funds and the statement clarifies ownership and power allocations; signature date is May 15, 2026.

Beta Bionics, Inc. Schedule 13G/A Amendment No. 4 reports holdings by Farallon-related entities and Zone Healthcare Holdings, LLC. Zone Healthcare Holdings, LLC is shown with 2,560,220 shares (5.8%). Several Farallon funds and affiliated persons are shown with positions ranging from 28,440 to 436,671 shares. A group of Farallon individual reporting persons are each reported with 3,607,920 shares (8.1%) in the cover rows incorporated by reference.

The filing lists ownership, voting and dispositive power columns for each reporting person and includes standard disclaimers about beneficial ownership and group status under Section 240.13d-1(c). Signatures show the filing was executed by Hannah E. Dunn on 05/12/2026.

Beta Bionics, Inc. beneficial-ownership disclosure: a Soleus-affiliated group led by Guy Levy reports combined holdings of 4,354,501 shares, equal to 9.8% of common stock. The filing attributes 4,323,714 shares to Soleus Capital Management, L.P. and 1,703,961 shares to Soleus Private Equity Fund II, L.P. The percentage bases on 44,561,695 shares outstanding as of April 16, 2026 per the issuer's Form 10-Q cover. Ownership is shown as shared voting and dispositive power through related Soleus entities; declarants disclaim beneficial ownership except for Section 13(d) purposes.

Beta Bionics, Inc. reported strong revenue growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $27.6 million from $17.6 million a year earlier, driven by expanding adoption of the iLet insulin delivery system and recurring single-use products across both durable medical equipment and pharmacy benefit channels.

Gross profit nearly doubled to $16.4 million, but rising investments in research and development, sales and marketing, and general and administrative functions pushed operating expenses to $40.7 million, resulting in a net loss of $21.9 million, an improvement from $28.7 million in the prior-year period. The company ended the quarter with $30.3 million in cash, cash equivalents and restricted cash and $209.2 million in short- and long-term investments, supporting ongoing commercialization and pipeline development, including a patch pump and a bihormonal iLet system.

Beta Bionics, Inc. reported strong first quarter 2026 growth and raised its full year 2026 outlook. Net sales reached $27.6 million, up 57% from $17.6 million a year earlier, driven by both Durable Medical Equipment and Pharmacy Benefit Plan channels.

Gross margin improved to 59.5% from 50.9%, while net loss narrowed to $21.9 million from $28.7 million as operating expenses increased to support growth. The company ended March 31, 2026 with $239.5 million in cash, cash equivalents, and investments and now expects 2026 revenue of $131–$136 million, higher gross margins, and a greater share of new patient starts through the PBP channel.

Beta Bionics, Inc. is holding a virtual 2026 Annual Meeting of Stockholders on May 21, 2026 at 2:00 P.M. Pacific Time, accessible via live audio webcast at www.virtualshareholdermeeting.com/BBNX2026 for holders as of March 23, 2026.

Stockholders are asked to elect two Class I directors, Sean Carney and Christy Jones, to terms ending at the 2029 annual meeting and to ratify Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy also details board structure, committee responsibilities, executive compensation, equity plans, auditor fees and corporate governance policies, including risk oversight, cybersecurity and stockholder engagement.